Modella said that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio.
Digital asset treasury companies currently included in MSCI Indexes will continue to remain, provided they meet all other index inclusion requirements, it said.
The investment is $500 million more than initially planned, intended to support the enhanced manufacturing capability of a broader range of medicines, according to the company.